Casdin Capital’s CRISPR Therapeutics CRSP Stock Holding History

Casdin Capital’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-266,430	Closed	-$20.2M	–	50
2021 Q4	$20.2M	Hold	266,430	–	–	0.57%	35
2021 Q3	$29.8M	Hold	266,430	–	–	0.74%	35
2021 Q2	$43.1M	Hold	266,430	–	–	1.09%	27
2021 Q1	$32.5M	Hold	266,430	–	–	0.97%	27
2020 Q4	$40.8M	Hold	266,430	–	–	1.21%	21
2020 Q3	$22.3M	Hold	266,430	–	–	1%	24
2020 Q2	$19.6M	Hold	266,430	–	–	1.16%	26
2020 Q1	$11.3M	Buy	+266,430	New	+$13.8M	1.2%	24
2018 Q4	–	Sell	-220,000	Closed	-$9.76M	–	32
2018 Q3	$9.76M	Hold	220,000	–	–	1.19%	24
2018 Q2	$12.9M	Buy	220,000 +85,000	+63%	+$4.84M	1.81%	19
2018 Q1	$6.17M	Buy	+135,000	New	+$5.57M	1.09%	23

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Casdin Capital's CRSP Position: Q1 2022 in Review

Casdin Capital sold out of CRISPR Therapeutics (CRSP) in Q1 2022, closing a stake of 266,430 shares — an estimated $20.2M sold.

Casdin Capital first reported a position in CRSP in Q1 2018 and held it in 11 quarters. The position peaked at $43.1M in Q2 2021. 447 funds tracked by Wall St. Rank hold CRSP as of Q1 2022.

Casdin Capital reported no remaining CRISPR Therapeutics position as of Q1 2022 after selling out during the quarter.
Casdin Capital sold 266,430 CRISPR Therapeutics shares in Q1 2022, an estimated $20.2M.
Casdin Capital first reported a position in CRISPR Therapeutics in Q1 2018 and held it in 11 quarters.
Casdin Capital's CRISPR Therapeutics position peaked at $43.1M in Q2 2021.
447 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2022.

Based on Casdin Capital's 13F filing for Q1 2022, filed 16 May 2022.